Navigation Links
Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent
Date:9/24/2010

sel Revascularization (TVR) and Target Lesion Failure (TLF) rates at the same follow-up times.  The lesions treated are single de novo native coronary lesions ranging in diameter from greater than or equal to 2.5 mm and less than or equal to 3.5 mm and less than or equal to 20 mm in length.

"The concept and design of the Combo Stent can provide a safe alternative for patients with a high risk of restenosis," said Alexandre Abizaid, M.D., Ph.D., director of the catheterization laboratory at the Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, and a principal investigator of the study. "We look forward to obtaining data from the REMEDEE study to determine the Combo Stent's potential."

The Combo Stent is designed to combine the pro-healing technology used in OrbusNeich's Genous™ Bio-engineered R stent™ for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation.  

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... MOUNTAIN VIEW, Calif. , May 21, 2013 /PRNewswire/ ... Brazil , Russia , ... (BRIC) are realizing there are no shortcuts.  This ... especially in the United States.  Companies must change the ... establishing value, customizing to local needs, and building regional ...
(Date:5/21/2013)... -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: ... cell based therapies for various personal applications, announced that ... CEO, will be presenting at the Marcum MicroCap Conference.   ... Thursday, May 30, 2013 at the Grand Hyatt Hotel, ... City.  Mr. Weinreb,s presentation will take place at 2:30 ...
(Date:5/21/2013)... 21, 2013  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization ... acute and breakthrough pain, today announced top-line ... 3 study of its investigational sublingual Sufentanil ... the primary efficacy endpoint was achieved.  The ...
Breaking Medicine Technology:Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... Pharmaceutical and healthcare market research company ... report, " Consumer Online Health Video : ... consumer demand for online health video and the impact ... health video has increased significantly among U.S. consumers online ...
... U.S. hospitals today reported significant progress in the fight ... and presented by clinicians from St. Joseph,s Mercy Hospital ... and the VA Medical Center in Seattle showed that ... some 62,500 hospital patients nationwide. (Logo: ...
Cached Medicine Technology:New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format 2Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 2Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 3Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 4
(Date:5/21/2013)... Mass. (PRWEB) May 21, 2013 Dimensional ... today announced that Western Maryland Health System, ... be using The Diver Solution™ (Diver) to help it ... is the first customer to purchase Diver through Dimensional ... , Like most hospitals, Western Maryland has massive ...
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Tools4ever, ... solutions, has made its Self Service Reset Password Management ... SSRPM, employees can now use the service on mobile ... that end users can easily reset their Windows passwords ... set of questions correctly, the user may then reset ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Thousands of ... from the lung condition known as chronic obstructive ... that patients placed on the common antibiotic azithromycin ... due to flare-ups of the disease. "Given ... of such events is critical," said Victoria Richards, ...
(Date:5/21/2013)... physical activity appears to be an independent predictor ... pulmonary disease (COPD) will end up being hospitalized, ... in Connecticut. The study also corroborates an earlier ... an increased incidence of hospitalizations among patients with ... be presented at the ATS 2013 International Conference. ...
(Date:5/21/2013)... 2013 Barbara Michels, author of “ ... over 50 years of experience in the world of ... both her mom and dad to Alzheimer’s disease ... volunteer with the New Mexico Chapter of the Alzheimer’s ... and insight into the many challenges caregivers experience. Through ...
Breaking Medicine News(10 mins):Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3Health News:Exercise levels may predict hospitalizations in COPD population 2Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 2Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 3Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 4
... Accelerated growth of tumors seen in mouse study , , ... in the inorganic phosphates found in many natural and ... rats, South Korean researchers report. , "Our study suggests ... for lung cancer treatment as well as prevention," Myung-Haing ...
... among those whose families don,t accept them , , MONDAY, ... families rejected them when they were younger are more ... use and suicide attempts, new research suggests. , The ... a child,s sexuality directly causes problems later in life. ...
... high-fat diet can not only lead to overweight because ... balance of circadian rhythms everyone,s 24-hour biological clock, ... The biological clock regulates the expression and/or activity of ... the clock can lead to such phenomena as hormone ...
... Second Harvest Heartland, the,Upper Midwest,s largest hunger relief ... General Mills and NBC,s "The Biggest Loser.",Through the ... dieters,in Minnesota and western Wisconsin pledge to lose ... cents to Second Harvest Heartland -- enough to ...
... bean plant Ricinus communis is considered one of the ... tissue damage and inflammation and can result in death. ... of castor beans whereby the toxin is released after ... severe gastrointestinal damage with symptoms and death due to ...
... for the relief of fever, headaches, and other minor ... are well documented and acetaminophen is accepted to be ... of short-term, especially high-dose NSAID and acetaminophen use have ... be published on November 21 , 2008 in the ...
Cached Medicine News:Health News:Food Phosphates Might Spur Lung Cancer 2Health News:Food Phosphates Might Spur Lung Cancer 3Health News:Rejection of Gay Teens Linked to Later Troubles 2Health News:Rejection of Gay Teens Linked to Later Troubles 3Health News:Another reason to avoid high-fat diet -- it can disrupt our biological clock 2Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 2Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 3Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 4Health News:Acute gastric injury due to high-dose analgesics? 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... reduces joint instability without disturbing hand ... comfortable and easy for users to ... and Robert V. Sypher Jr., MD, ... response to patients' complaints of discomfort ...
... The ThumSaver MP stabilizes the MP joint and the ... to reduce subluxation of both of the thumb joints. ... to eliminate pain, but who need maximum mobility for ... base of the thumb and for those with pain ...
... thumb splint is molded from rigid plastic in ... application and wearing comfort. The uniquely sculpted ... fingers and preserves maximum function of the hand. ... DeQuervain's Tendonitis, strains and sprains of the MCP ...
Medicine Products: